--- title: "Curaleaf (OTCMKTS:CURLF) Shares Gap Down - What's Next?" type: "News" locale: "en" url: "https://longbridge.com/en/news/278428466.md" description: "Curaleaf Holdings, Inc. (OTCMKTS:CURLF) shares gapped down from $2.37 to $2.21 before trading at $2.25. Analysts have mixed ratings, with Zacks upgrading to 'hold' and ATB Cormark to 'outperform'. Curaleaf reported a quarterly EPS of ($0.05), exceeding estimates, with revenue of $333.07 million. The company has a market cap of $1.54 billion and a negative net margin of 18.08%. Despite a current 'Buy' consensus, some analysts suggest better investment opportunities exist." datetime: "2026-03-09T17:23:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278428466.md) - [en](https://longbridge.com/en/news/278428466.md) - [zh-HK](https://longbridge.com/zh-HK/news/278428466.md) --- # Curaleaf (OTCMKTS:CURLF) Shares Gap Down - What's Next? Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $2.37, but opened at $2.21. Curaleaf shares last traded at $2.25, with a volume of 45,165 shares changing hands. ## Analysts Set New Price Targets - Cannabis Stocks Up for Reversal: Pipedreams or Opportunity? Several equities research analysts have recently commented on the stock. Zacks Research raised shares of Curaleaf from a "strong sell" rating to a "hold" rating in a research report on Thursday, January 1st. ATB Cormark Capital Markets raised shares of Curaleaf to an "outperform" rating in a research report on Tuesday, December 2nd. Finally, Alliance Global Partners reissued a "buy" rating on shares of Curaleaf in a report on Monday, December 22nd. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy". **View Our Latest Report on Curaleaf** ## Curaleaf Trading Down 4.2% - 3 Growing Cannabis Stocks Ready To Bloom The company has a debt-to-equity ratio of 1.14, a quick ratio of 0.76 and a current ratio of 1.52. The firm has a 50 day simple moving average of $2.45 and a two-hundred day simple moving average of $2.68. The firm has a market capitalization of $1.54 billion, a P/E ratio of -7.57 and a beta of 0.71. Curaleaf (OTCMKTS:CURLF - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03. The firm had revenue of $333.07 million for the quarter, compared to the consensus estimate of $328.70 million. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 23.17%. Equities research analysts forecast that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current year. ## Curaleaf Company Profile (Get Free Report) - Can The SAFE Act Light Up High Hopes For Cannabis Industry? Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company's vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements. Curaleaf's product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates. ## Featured Stories - Five stocks we like better than Curaleaf - The gold chart Wall Street is terrified of… - America’s 1776 happening again - What a Former CIA Agent Knows About the Coming Collapse - Elon Musk already made me a “wealthy man” - Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Curaleaf Right Now? Before you consider Curaleaf, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list. While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [CURLF.US](https://longbridge.com/en/quote/CURLF.US.md) ## Related News & Research - [Curaleaf Launches Share Repurchase Program | CURLF Stock News](https://longbridge.com/en/news/282992694.md) - [Curaleaf Announces Executive Automatic Securities Disposition Plan | CURLF Stock News](https://longbridge.com/en/news/281572544.md) - [Crude Prices Jump as US Blockade of Strait of Hormuz Takes Hold](https://longbridge.com/en/news/282566428.md) - [ANALYSIS-Sazerac won’t easily gatecrash Jack Daniel's-maker's merger talks](https://longbridge.com/en/news/282631137.md) - [Antalpha Platform Holding CEO and COO step down](https://longbridge.com/en/news/282743566.md)